Steris Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Steris Plc on November 18, 2020. The filing primarily addresses the closing of the acquisition of Key Surgical LLC and the entry into a new material definitive agreement to finance this transaction.
Key Financial Metrics and Debt Structure
The filing details a new Term Loan Agreement with the following characteristics:
- Loan Amount: $550 million.
- Purpose: Funding a portion of the Key Surgical acquisition purchase price, prepaying existing Key Surgical indebtedness, and covering transaction fees.
- Maturity Date: November 20, 2023.
- Principal Repayment Schedule:
- No principal payments due through December 31, 2021.
- Quarterly payments of 1.25% of the original principal from January 1, 2022, through December 31, 2022.
- Quarterly payments of 1.875% of the original principal from January 1, 2023, through September 30, 2023.
- Bullet payment of the remaining balance due on November 20, 2023.
- Interest Rate: Base Rate or Eurocurrency Rate plus an Applicable Margin based on the Consolidated Total Debt to Consolidated EBITDA ratio.
- Covenants: Includes limitations on leverage, minimum interest coverage, restrictions on indebtedness by non-guarantor subsidiaries, and lien creation.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.
Material Changes
The primary material change is the incurrence of $550 million in new debt and the completion of the acquisition of Key Surgical LLC. This transaction alters the company's capital structure and debt obligations effective November 18, 2020.
Outlook, Risks, and Contingencies
Management highlights several risks and forward-looking uncertainties, including:
- Acquisition Integration: Risks that anticipated financial results or benefits from the Key Surgical acquisition may not be realized.
- Redomiciliation: Uncertainty regarding accounting and tax treatments following the company's redomiciliation to Ireland.
- Regulatory and Tax: Potential changes in tax laws, FDA/EPA regulatory actions, and the impact of the Tax Cuts and Jobs Act (TCJA).
- Macro Factors: Impacts of the COVID-19 pandemic, Brexit, international unrest, and credit market contractions.
- Operational Risks: Potential for increased operating costs, customer loss, or supply chain disruptions.
Investor Verification Checklist
- Verify the total purchase price of Key Surgical LLC and the proportion funded by the new $550 million term loan versus other sources.
- Review the full Credit Agreement (Exhibit 10.1) to understand the specific calculation of the Applicable Margin and the precise definition of Consolidated EBITDA.
- Assess the impact of the new debt service obligations on the company's existing liquidity and leverage ratios.
- Monitor the integration progress of Key Surgical to ensure anticipated synergies are being realized.
- Review the press release (Exhibit 99.1) for additional details on the strategic rationale for the acquisition.